Source: Cancers. Unidades: FM, IQ, ICB
Subjects: PARASITOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, NEOPLASIAS CEREBRAIS, GLIOMA, LIPOPOLISSACARÍDEOS, ANTIOXIDANTES, ANTIDIABÉTICOS (HIPOGLICEMIANTES), ESTRESSE OXIDATIVO, APOPTOSE
ABNT
MORETTI, Isabele Fattori et al. GBM cells Exhibit susceptibility to metformin treatment according to TLR4 pathway activation and metabolic and antioxidant status. Cancers, v. 15, n. 3, p. 1-18, 2023Tradução . . Disponível em: https://doi.org/10.3390/cancers15030587. Acesso em: 18 nov. 2024.APA
Moretti, I. F., Lerario, A. M., Sola, P. R., Silva, J. M. da, Baptista, M. da S., Palmisano, G., et al. (2023). GBM cells Exhibit susceptibility to metformin treatment according to TLR4 pathway activation and metabolic and antioxidant status. Cancers, 15( 3), 1-18. doi:10.3390/cancers15030587NLM
Moretti IF, Lerario AM, Sola PR, Silva JM da, Baptista M da S, Palmisano G, Shinjo SMO, Marie SKN. GBM cells Exhibit susceptibility to metformin treatment according to TLR4 pathway activation and metabolic and antioxidant status [Internet]. Cancers. 2023 ; 15( 3): 1-18.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/cancers15030587Vancouver
Moretti IF, Lerario AM, Sola PR, Silva JM da, Baptista M da S, Palmisano G, Shinjo SMO, Marie SKN. GBM cells Exhibit susceptibility to metformin treatment according to TLR4 pathway activation and metabolic and antioxidant status [Internet]. Cancers. 2023 ; 15( 3): 1-18.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/cancers15030587